Prevention, screening and treatment of colorectal cancer: a global and regional generalized cost effectiveness analysis

Table 1 Estimated Effects of Interventions (based on model of AMRA region) and assumed Compliance data that were inputted into POPMOD model.

Intervention	Description	Decrease in Incidence	Decrease in Case-Fatality Rate	Compliance
FOB1	Annual Fecal Occult Blood Tests^a	35.0%	0%	56.8%
FOB2	Biannual Fecal Occult Blood Tests^a	21.9%	0%	61.8%
SIG5	Sigmoidoscopy every 5 years[1]^a	38.9%	0%	45.0%
COL10	Colonoscopy every 10 years^a	52.6%	0%	45.0%
FOB1SIG5	Annual FOBT, SIG every 5 years^a	51.5%	0%	45.0%
FOB50	FOBT at age 50^a	2.6%	0%	71.8%
SIG50	Sigmoidoscopy at age 50^a	11.8%	0%	55.0%
COL50	Colonoscopy at age 50^a	25.9%	0%	55.0%
FOBSIG50	FOBT & SIG at age 50^a	13.2%	0%	55.0%
RX	Medical Treatment of cancers^b	0%	91.9%	100%
FOB1RX	Combination of FOB1 & RX	35.0%	17.9%^c	56.8%
FOB2RX	Combination of FOB2 & RX	21.9%	12.9%^c	61.8%
SIG5RX	Combination of SIG5 & RX	38.9%	3.4%^c	45.0%
COL10RX	Combination of COL10 & RX	52.6%	3.9%^c	45.0%
FOB1SIG5RX	Combination of FOB1SIG5 & RX	51.5%	18.3%^c	45.0%
FOB50RX	Combination of FOB50 & RX	2.6%	0.5%^c	71.8%
SIG50RX	Combination of SIG50& RX	11.8%	0.3%^c	55.0%
COL50RX	Combination of COL50& RX	25.9%	0.4%^c	55.0%
FOBSIG50RX	Combination of FOBSIG50 & RX	13.2%	0.5%^c	55.0%
FVCAMP	Fruit & Vegetables campaign	d)	0%	---
FVCAMPRX	Combination of FVCAMP & RX	d)	0%^c	---
DRE1	Digital Rectal Exam annually^a	17.6%	0%	50%
DRE1RX	Combination of DRE1 & RX	17.6%	1.8%^c	50%

Notes:
Subscripts 1,2,5,10 (eg: SIG5] in the intervention column denote the frequency of screening in years.
Subscript 50, denotes a one off intervention at age 50.
RX denotes the availabily of treatments for cancers in addition to the intervention program.
Efficacy varied slightly between regions due to demographic differences.
Efficacy considered on an age-sex specific basis.
a) Denotes colonoscopy performed on all positive tests, with subsequent removal of lesions or polyps if discovered.
b) Including surgical, radiotherapy and chemotherapy.
c) In excess of decrease in CFR caused by treatment.
d) Varies by region

ISSN: 1478-7547